HRP20090678T1 - Cjepivo za sprječavanje i liječenje infekcije hiv-om - Google Patents
Cjepivo za sprječavanje i liječenje infekcije hiv-om Download PDFInfo
- Publication number
- HRP20090678T1 HRP20090678T1 HR20090678T HRP20090678T HRP20090678T1 HR P20090678 T1 HRP20090678 T1 HR P20090678T1 HR 20090678 T HR20090678 T HR 20090678T HR P20090678 T HRP20090678 T HR P20090678T HR P20090678 T1 HRP20090678 T1 HR P20090678T1
- Authority
- HR
- Croatia
- Prior art keywords
- gag
- polypeptide
- nef
- preparation
- fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Polipeptid, naznačen time što sadrži Nef ili njegov imunogeni fragment ili derivat, p17 Gag i p24 Gag ili njihove imunogene fragmente ili derivate, gdje je najmanje jedan HIV antigen ili njegov imunogeni fragment prisutan između p17 Gag i p24 Gag, gdje navedeni polipeptid dodatno sadrži RT ili njegov imunogeni fragment ili derivat, gdje navedeni imunogeni fragmenti ili derivati zadržavaju sposobnost poticanja imunosnog odgovora na nativni antigen. Patent sadrži još 19 patentnih zahtjeva.
Claims (20)
1. Polipeptid, naznačen time što sadrži Nef ili njegov imunogeni fragment ili derivat, p17 Gag i p24 Gag ili njihove imunogene fragmente ili derivate, gdje je najmanje jedan HIV antigen ili njegov imunogeni fragment prisutan između p17 Gag i p24 Gag, gdje navedeni polipeptid dodatno sadrži RT ili njegov imunogeni fragment ili derivat, gdje navedeni imunogeni fragmenti ili derivati zadržavaju sposobnost poticanja imunosnog odgovora na nativni antigen.
2. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži Pol ili njegov imunogeni fragment ili derivat, gdje navedeni imunogen fragmenti ili derivat zadržava sposobnost poticanja imunosnog odgovora na nativni antigen.
3. Polipeptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što RT ili njegov imunogeni fragment je fragment u kojem je RT skraćen, tako da mu nedostaje domena RNaze H na karboksi kraju.
4. Polipeptid u skladu s patentnim zahtjevom 3, naznačen time što RT fragment je p51 fragment.
5. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačen time što RT sadrži mutaciju na položaju 592, radi zamjene metionina drugim ostatkom, primjerice lizinom.
6. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što Nef je Nef pune duljine.
7. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između jednog od sljedećeg:
1. p24 Gag-RT-Nef-p17 Gag
2. p24 Gag-RT*-Nef-p17 Gag
3. p24 Gag-p51 RT-Nef-p17 Gag
4. p24 Gag-p51 RT*-Nef-p17 Gag
gdje * predstavlja mutaciju metionina592 u lizin u RT-u.
8. Postupak pročišćavanja polipeptida u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što navedeni postupak se sastoji u:
i) pripravi pripravka koji sadrži nepročišćeni polipeptid;
ii) podvrgavanju navedenog pripravka najmanje dva koraka kromatografije;
iii) izbornom karboksiamidiranju navedenog polipeptida;
iv) provođenju koraka izmjene pufera kako bi se dobilo protein u puferu pogodnom za farmaceutsku formulaciju.
9. Postupak u skladu s patentnim zahtjevom 8, naznačen time što se kromatografiju provodi u najviše dva koraka.
10. Postupak u skladu s patentnim zahtjevom 8 ili patentnim zahtjevom 9, naznačen time što karboksiamidiranje se provodi između dva koraka kromatografije.
11. Pripravak, naznačen time što sadrži polipeptid u skladu s patentnim zahtjevom 1.
12. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što RT ili njegov imunogeni fragment je fragment u kojem je RT skraćen, tako da mu nedostaje domena RNaze H na C-kraju.
13. Pripravak u skladu s patentnim zahtjevom 12, naznačen time što RT fragment je p51 fragment.
14. Pripravak u skladu s bilo kojim od patentnih zahtjeva 11 do 13, naznačen time što RT sadrži mutaciju na položaju 592, radi zamjene metionina drugim ostatkom, primjerice lizinom.
15. Pripravak u skladu s bilo kojim od patentnih zahtjeva 11 do 14, naznačen time što Nef je Nef pune duljine.
16. Polinukleotid ili polinukleotidi, naznačeni time što kodiraju polipeptid, ili pripravak polipeptida u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i 11 do 15.
17. Farmaceutski pripravak, naznačen time što sadrži polipeptid ili polinukleotid ili pripravak polipeptida ili polinukleotida u skladu s bilo kojim od prethodnih patentnih zahtjeva, zajedno s farmaceutski prihvatljivom podlogom ili adjuvansom.
18. Farmaceutski pripravak u skladu s patentnim zahtjevom 17, naznačen time što adjuvans je adjuvans koji inducira TH1, poput QS21 ili 3D-MPL, ili kombinacija QS21 i 3D-MPL.
19. Farmaceutski komplet, naznačen time što sadrži:
a) pripravak koji sadrži polipeptid u skladu s patentnim zahtjevom 1, zajedno s farmaceutski prihvatljivom pomoćnom tvari, i
b) pripravak koji sadrži polinukleotid koji kodira jedan ili više od Nef ili Gag ili imunogeni fragment ili derivat Nef ili Gag, koji sadrži epitop Nef ili Gag prisutan u polipeptidu iz a), zajedno s farmaceutski prihvatljivom pomoćnom tvari, gdje bilo koji imunogeni fragment ili derivat zadržava sposobnost poticanja imunosnog odgovora na nativni antigen.
20. Farmaceutski komplet, naznačen time što sadrži:
a) pripravak koji sadrži polinukleotid koji kodira polipeptid u skladu s patentnim zahtjevom 1, zajedno s farmaceutski prihvatljivom pomoćnom tvari, i
b) pripravak koji sadrži polipeptid koji sadrži jedan ili više od Nef ili Gag ili imunogeni fragment ili derivat Nef ili Gag, koji sadrži epitop Nef ili Gag prisutan u polipeptidu iz a), zajedno s farmaceutski prihvatljivom pomoćnom tvari, gdje bilo koji imunogeni fragment ili derivat zadržava sposobnost poticanja imunosnog odgovora na nativni antigen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0417494.2A GB0417494D0 (en) | 2004-08-05 | 2004-08-05 | Vaccine |
| PCT/EP2005/008434 WO2006013106A2 (en) | 2004-08-05 | 2005-08-03 | Vaccine for prevention and treatment of hiv-infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090678T1 true HRP20090678T1 (hr) | 2010-01-31 |
Family
ID=32982606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090678T HRP20090678T1 (hr) | 2004-08-05 | 2009-12-17 | Cjepivo za sprječavanje i liječenje infekcije hiv-om |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7612173B2 (hr) |
| EP (3) | EP1773999B1 (hr) |
| JP (3) | JP2008507987A (hr) |
| KR (1) | KR101501495B1 (hr) |
| CN (2) | CN102633866B (hr) |
| AR (2) | AR050102A1 (hr) |
| AT (1) | ATE443769T1 (hr) |
| AU (1) | AU2005268856B2 (hr) |
| BR (1) | BRPI0514108A (hr) |
| CA (1) | CA2575898C (hr) |
| CY (1) | CY1109667T1 (hr) |
| DE (1) | DE602005016810D1 (hr) |
| DK (1) | DK1773999T3 (hr) |
| ES (3) | ES2486669T3 (hr) |
| GB (1) | GB0417494D0 (hr) |
| HK (1) | HK1108168A1 (hr) |
| HR (1) | HRP20090678T1 (hr) |
| IL (2) | IL180947A0 (hr) |
| MA (1) | MA28983B1 (hr) |
| MX (1) | MX2007001515A (hr) |
| MY (1) | MY145614A (hr) |
| NO (1) | NO20070988L (hr) |
| NZ (1) | NZ552976A (hr) |
| PE (1) | PE20060577A1 (hr) |
| PL (1) | PL1773999T3 (hr) |
| PT (1) | PT1773999E (hr) |
| RU (1) | RU2441878C2 (hr) |
| SG (1) | SG155206A1 (hr) |
| SI (1) | SI1773999T1 (hr) |
| TW (1) | TWI365191B (hr) |
| WO (1) | WO2006013106A2 (hr) |
| ZA (1) | ZA200700771B (hr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
| EP1039880A1 (en) * | 1998-10-23 | 2000-10-04 | Idea Innovative Dermale Applikationen GmbH | Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates |
| ATE216875T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Nichtinvasive impfung durch die haut |
| EP1031347B1 (en) | 1999-01-27 | 2002-04-17 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
| WO2001001962A1 (en) * | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| EP1811961A2 (en) * | 2004-11-12 | 2007-08-01 | Idea Ag | Extended surface aggregates in the treatment of skin conditions |
| TW200716750A (en) * | 2005-05-12 | 2007-05-01 | Glaxo Group Ltd | Vaccine composition |
| EP2963118B1 (en) | 2005-06-01 | 2017-08-09 | California Institute of Technology | Method of targeted gene delivery using viral vectors |
| JP2009536653A (ja) * | 2006-05-09 | 2009-10-15 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | Ｈｉｖ−１免疫原性組成物 |
| PT2048955E (pt) * | 2006-07-21 | 2013-09-20 | California Inst Of Techn | Administração de gene alvo para vacinação de células dendríticas |
| PL2137210T3 (pl) * | 2007-03-02 | 2017-06-30 | Glaxosmithkline Biologicals Sa | Nowy sposób i kompozycje |
| US9717788B2 (en) * | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
| US20110244496A1 (en) * | 2007-03-06 | 2011-10-06 | Rutgers, The State University | Hiv reverse transcriptase compositions and methods |
| EP2142212A2 (en) * | 2007-03-26 | 2010-01-13 | International Aids Vaccine Initiative | Method of elicting immune response with a modified mva viral hiv-1 vector |
| KR101238795B1 (ko) | 2007-05-24 | 2013-03-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 동결건조 항원 조성물 |
| AU2008339984A1 (en) * | 2007-12-21 | 2009-07-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
| NZ596171A (en) | 2008-07-16 | 2012-05-25 | Baylor Res Inst | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| GB0815872D0 (en) * | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| EP2344143A1 (en) | 2008-09-09 | 2011-07-20 | Mukesh Harilal Shukla | Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same |
| MX2012001075A (es) | 2009-07-24 | 2012-05-22 | Immune Design Corp | Vectores lentivirales pseudotipificados con una glicoproteina de envoltura de virus sindbis. |
| WO2011117408A1 (en) * | 2010-03-26 | 2011-09-29 | Glaxosmithkline Biologicals S.A. | Hiv vaccine |
| JP6030052B2 (ja) * | 2010-05-14 | 2016-11-24 | バクスアルタ インコーポレイテッド | Ｏｓｐａキメラおよびそのワクチンでの使用法 |
| EP2621528A1 (en) * | 2010-09-27 | 2013-08-07 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| JP2012120506A (ja) * | 2010-12-10 | 2012-06-28 | Tosoh Corp | Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法 |
| GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
| JP2013146235A (ja) * | 2012-01-20 | 2013-08-01 | Tosoh Corp | トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法 |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| MX362699B (es) | 2012-03-30 | 2019-02-01 | Immune Design Corp | Partículas de vectores lentivirales teniendo eficiencia de transducción mejorada para células que expresan dc-sign. |
| WO2014160747A2 (en) | 2013-03-26 | 2014-10-02 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| PL3166607T3 (pl) | 2014-07-11 | 2023-02-20 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych do leczenia hiv |
| KR102014518B1 (ko) | 2017-01-05 | 2019-08-26 | 서울대학교산학협력단 | HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신 |
| GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| BR112022009421A2 (pt) | 2019-11-14 | 2022-10-25 | Aelix Therapeutics S L | Regimes de dosagem para vacinas |
| CN115666634A (zh) | 2020-03-27 | 2023-01-31 | 瑞典疫苗制药有限公司 | 用于治疗和预防冠状病毒的组合物和方法 |
| EP4277652A1 (en) | 2021-01-14 | 2023-11-22 | Gilead Sciences, Inc. | Hiv vaccines and methods of using |
| TW202330575A (zh) | 2021-09-29 | 2023-08-01 | 瑞典商斯文斯卡疫苗生產股份有限公司 | 用於治療及預防冠狀病毒之組成物及方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| DE3300234A1 (de) | 1983-01-05 | 1984-07-05 | Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim | Etagenturm zur warenausstellung |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| DK643188A (da) * | 1987-11-24 | 1989-05-25 | Smithkline Biolog | Ekspression af hiv-proteiner i e.coli og s.cerevisiae |
| US5221610A (en) * | 1988-05-26 | 1993-06-22 | Institut Pasteur | Diagnostic method and composition for early detection of HIV infection |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
| KR0172970B1 (ko) | 1992-06-17 | 1999-02-01 | 김영길 | Aids백신에 유용한 키메릭 단백 및 그의 제조방법 |
| DK0761231T3 (da) | 1992-06-25 | 2000-05-08 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
| DE69405551T3 (de) | 1993-03-23 | 2005-10-20 | Smithkline Beecham Biologicals S.A. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| US5962635A (en) * | 1993-05-18 | 1999-10-05 | Biomolecular Research Institute Ltd. | Therapeutic compounds |
| WO1995014026A1 (en) | 1993-11-17 | 1995-05-26 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| AU4992197A (en) | 1996-10-11 | 1998-05-11 | Regents Of The University Of California, The | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| JP5220248B2 (ja) | 1997-08-29 | 2013-06-26 | アンチジェニックス・インコーポレイテッド | アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物 |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
| AU762376C (en) | 1998-08-04 | 2004-10-14 | Henry M. Jackson Foundation, The | Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response |
| AU782193B2 (en) | 1999-12-17 | 2005-07-07 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef |
| DK1240186T3 (da) * | 1999-12-23 | 2010-05-31 | Medical Res Council | Forbedringer i eller relateret til immunrespons mod HIV |
| US20020155127A1 (en) * | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| AU2001294562B2 (en) | 2000-09-15 | 2007-05-24 | Merck & Co., Inc. | Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications |
| CU23235A1 (es) | 2001-02-28 | 2007-09-26 | Ct Ingenieria Genetica Biotech | POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA |
| EP1434859A2 (en) * | 2001-07-25 | 2004-07-07 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| EP1427826B1 (en) * | 2001-09-20 | 2011-04-20 | Glaxo Group Limited | HIV- RT-nef-Gag codon optimised DNA vaccines |
| IL161584A0 (en) | 2001-11-21 | 2004-09-27 | Univ Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| AU2002360429A1 (en) | 2001-11-26 | 2003-06-10 | Avigen, Inc. | Methods for producing stocks of recombinant aav virions |
| US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
| US20050266024A1 (en) * | 2002-03-19 | 2005-12-01 | Powdermed Limited | Adjuvant |
| ES2285174T3 (es) * | 2002-06-11 | 2007-11-16 | Glaxosmithkline Biologicals S.A. | Composiciones inmunogenicas. |
| GB0225788D0 (en) | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| US7501503B2 (en) * | 2002-12-31 | 2009-03-10 | Mcgill University | Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase |
| US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
| CA2539864A1 (en) | 2003-09-24 | 2005-04-07 | Oxxon Therapeutics Limited | Hiv pharmaccines |
-
2004
- 2004-08-05 GB GBGB0417494.2A patent/GB0417494D0/en not_active Ceased
-
2005
- 2005-08-02 PE PE2005000896A patent/PE20060577A1/es not_active Application Discontinuation
- 2005-08-03 KR KR1020077005049A patent/KR101501495B1/ko not_active Expired - Fee Related
- 2005-08-03 SG SG200905319-0A patent/SG155206A1/en unknown
- 2005-08-03 PL PL05769948T patent/PL1773999T3/pl unknown
- 2005-08-03 CN CN201110406267.7A patent/CN102633866B/zh not_active Expired - Fee Related
- 2005-08-03 SI SI200530868T patent/SI1773999T1/sl unknown
- 2005-08-03 RU RU2007104088/10A patent/RU2441878C2/ru not_active IP Right Cessation
- 2005-08-03 WO PCT/EP2005/008434 patent/WO2006013106A2/en active Application Filing
- 2005-08-03 ES ES10178939.4T patent/ES2486669T3/es active Active
- 2005-08-03 MX MX2007001515A patent/MX2007001515A/es active IP Right Grant
- 2005-08-03 EP EP05769948A patent/EP1773999B1/en active Active
- 2005-08-03 CA CA2575898A patent/CA2575898C/en active Active
- 2005-08-03 PT PT05769948T patent/PT1773999E/pt unknown
- 2005-08-03 MY MYPI20053623A patent/MY145614A/en unknown
- 2005-08-03 CN CN2005800340055A patent/CN101035897B/zh not_active Expired - Fee Related
- 2005-08-03 DK DK05769948.0T patent/DK1773999T3/da active
- 2005-08-03 DE DE602005016810T patent/DE602005016810D1/de active Active
- 2005-08-03 EP EP10178939.4A patent/EP2280073B1/en active Active
- 2005-08-03 JP JP2007524281A patent/JP2008507987A/ja active Pending
- 2005-08-03 ES ES05769948T patent/ES2334044T3/es active Active
- 2005-08-03 AT AT05769948T patent/ATE443769T1/de active
- 2005-08-03 NZ NZ552976A patent/NZ552976A/en not_active IP Right Cessation
- 2005-08-03 AU AU2005268856A patent/AU2005268856B2/en not_active Ceased
- 2005-08-03 US US11/573,128 patent/US7612173B2/en active Active
- 2005-08-03 BR BRPI0514108-7A patent/BRPI0514108A/pt not_active IP Right Cessation
- 2005-08-03 EP EP09171029.3A patent/EP2130921B1/en active Active
- 2005-08-03 TW TW094126452A patent/TWI365191B/zh not_active IP Right Cessation
- 2005-08-03 ES ES09171029.3T patent/ES2445453T3/es active Active
- 2005-08-04 AR ARP050103260A patent/AR050102A1/es active IP Right Grant
-
2007
- 2007-01-25 IL IL180947A patent/IL180947A0/en not_active IP Right Cessation
- 2007-01-26 ZA ZA200700771A patent/ZA200700771B/xx unknown
- 2007-02-21 NO NO20070988A patent/NO20070988L/no not_active Application Discontinuation
- 2007-02-22 MA MA29713A patent/MA28983B1/fr unknown
- 2007-10-17 HK HK07111226.6A patent/HK1108168A1/xx not_active IP Right Cessation
-
2009
- 2009-10-14 US US12/578,969 patent/US20100184836A1/en not_active Abandoned
- 2009-12-16 CY CY20091101311T patent/CY1109667T1/el unknown
- 2009-12-17 HR HR20090678T patent/HRP20090678T1/hr unknown
-
2010
- 2010-08-12 IL IL207575A patent/IL207575A0/en unknown
-
2011
- 2011-02-18 AR ARP110100503A patent/AR080216A2/es not_active Application Discontinuation
- 2011-06-13 JP JP2011131445A patent/JP5629647B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-25 JP JP2014151365A patent/JP6007212B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090678T1 (hr) | Cjepivo za sprječavanje i liječenje infekcije hiv-om | |
| IL260135A (en) | Preparations and methods of neisseria meningitidis | |
| HRP20210608T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije | |
| RU2007127993A (ru) | Сахарид-конъюгатные вакцины | |
| AR059772A1 (es) | Composiciones que incuyen hemaglutinina metodos de elaboracion y metodos de uso de las mismas | |
| CO5700790A2 (es) | Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina | |
| EP2708549A3 (en) | Improved vaccines and methods for using the same | |
| AR065523A1 (es) | Procedimiento para fomentar una respuesta inmunitaria frente a un patogeno y composiciones | |
| WO2007081447A3 (en) | Norovirus and sapovirus antigens | |
| AR035586A1 (es) | Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn | |
| JP2016040284A5 (hr) | ||
| PE20091104A1 (es) | Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo | |
| DK1898948T3 (da) | Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans | |
| FI3452507T3 (fi) | Tau-immuunihoito | |
| RU2017129340A (ru) | Композиции nеisseria мeningitidis и способы их получения | |
| CA2434000A1 (en) | Adjuvant viral particle | |
| WO2006136460A3 (en) | New adjuvant | |
| BRPI0616224B8 (pt) | composição farmacêutica | |
| Garg et al. | Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain | |
| WO2018055535A3 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof | |
| EP1556513A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| NO20071030L (no) | Immunogene komplekser, metoder for fremstilling derav og bruk av samme i farmasoytiske sammensetninger. | |
| JP2006501249A5 (hr) | ||
| ATE408620T1 (de) | Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16 |